Atopic Dermatitis and Difficult-to-Treat Areas: A Case Series of Four Patients with Dupilumab-Resistant Primary Atopic Blepharitis and Successfully Treated with Upadacitinib

Bylund S , Kobyletzki LB , Svalstedt M , et al. Prevalence and incidence of atopic Dermatitis: a systematic review. Acta Derm Venereol. 2020; ;100(12):adv00160.

Blauvelt A , Teixeira HD , Simpson EL , et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic Dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2021; ;157(9):1047–1055. Erratum in: JAMA Dermatol. 2022 Feb 1;158(2):219. Erratum in: JAMA Dermatol. 2022 Feb 1;;157(9):219.

Simpson EL , Bieber T , Guttman-Yassky E , et al. Two phase 3 trials of dupilumab versus placebo in atopic Dermatitis. N Engl J Med. 2016; 375(24):2335–2348.

Licata G , Gambardella A , Tancredi V , et al. Face atopic Dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022; 36(2):e150–e152.